Formosa Pharmaceuticals, Inc. (TPE:6838)
Taiwan
· Delayed Price · Currency is TWD 27.80
-0.10 (-0.36%)
At close: Apr 29, 2026
Formosa Pharmaceuticals Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Revenue | 9.5 | 143.36 | 31.17 | 1.32 | 28.53 | Upgrade
|
| Revenue Growth (YoY) | -93.38% | 359.89% | 2270.49% | -95.39% | - | Upgrade
|
| Cost of Revenue | 11.09 | 24.37 | 3.83 | 0.98 | 0.27 | Upgrade
|
| Gross Profit | -1.6 | 118.99 | 27.35 | 0.33 | 28.26 | Upgrade
|
| Selling, General & Admin | 47.63 | 60.8 | 40.2 | 25.53 | 20.65 | Upgrade
|
| Research & Development | 121.38 | 226 | 270.18 | 356.47 | 387.62 | Upgrade
|
| Operating Expenses | 169.01 | 294.62 | 310.38 | 382 | 408.27 | Upgrade
|
| Operating Income | -170.61 | -175.63 | -283.04 | -381.67 | -380.01 | Upgrade
|
| Interest Expense | -0.49 | -0.57 | -4.31 | -0.99 | -2.21 | Upgrade
|
| Interest & Investment Income | 25.29 | 21.18 | 12.42 | 0.47 | 0.06 | Upgrade
|
| Currency Exchange Gain (Loss) | 13.96 | -18.62 | 9.29 | -25.15 | 20.97 | Upgrade
|
| Other Non Operating Income (Expenses) | 47.85 | 1.03 | 0.09 | 0.75 | 0.01 | Upgrade
|
| EBT Excluding Unusual Items | -84 | -172.61 | -265.54 | -406.59 | -361.18 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | -0.2 | Upgrade
|
| Other Unusual Items | - | -6.96 | -34.53 | - | -37.04 | Upgrade
|
| Pretax Income | -84 | -179.57 | -300.07 | -406.59 | -398.42 | Upgrade
|
| Income Tax Expense | -0.43 | 21.36 | 21.86 | -0.42 | 2.4 | Upgrade
|
| Earnings From Continuing Operations | -83.57 | -200.93 | -321.93 | -406.17 | -400.82 | Upgrade
|
| Minority Interest in Earnings | 0.01 | -0.08 | -0.03 | -0.1 | -0.06 | Upgrade
|
| Net Income | -83.57 | -201.01 | -321.96 | -406.27 | -400.88 | Upgrade
|
| Net Income to Common | -83.57 | -201.01 | -321.96 | -406.27 | -400.88 | Upgrade
|
| Shares Outstanding (Basic) | 151 | 141 | 124 | 105 | 92 | Upgrade
|
| Shares Outstanding (Diluted) | 151 | 141 | 124 | 105 | 92 | Upgrade
|
| Shares Change (YoY) | 7.22% | 13.48% | 18.00% | 13.70% | 31.19% | Upgrade
|
| EPS (Basic) | -0.55 | -1.43 | -2.59 | -3.86 | -4.33 | Upgrade
|
| EPS (Diluted) | -0.55 | -1.43 | -2.59 | -3.86 | -4.33 | Upgrade
|
| Free Cash Flow | -105.65 | -135.95 | -198.21 | -346.15 | -331.35 | Upgrade
|
| Free Cash Flow Per Share | -0.70 | -0.96 | -1.60 | -3.29 | -3.58 | Upgrade
|
| Gross Margin | -16.83% | 83.00% | 87.73% | 25.32% | 99.06% | Upgrade
|
| Operating Margin | -1796.85% | -122.51% | -907.98% | -29024.26% | -1332.01% | Upgrade
|
| Profit Margin | -880.10% | -140.22% | -1032.84% | -30895.21% | -1405.18% | Upgrade
|
| Free Cash Flow Margin | -1112.70% | -94.83% | -635.85% | -26323.19% | -1161.46% | Upgrade
|
| EBITDA | -128.45 | -139.99 | -247.53 | -345.56 | -345.41 | Upgrade
|
| EBITDA Margin | - | -97.65% | - | - | - | Upgrade
|
| D&A For EBITDA | 42.17 | 35.64 | 35.51 | 36.11 | 34.6 | Upgrade
|
| EBIT | -170.61 | -175.63 | -283.04 | -381.67 | -380.01 | Upgrade
|
| EBIT Margin | - | -122.51% | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.